Effects of Huperzine A in Treatment of Moderate to Severe TBI
|The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details.|
|ClinicalTrials.gov Identifier: NCT01676311|
Recruitment Status : Terminated (Insufficient accrual rate: 14 participants enrolled (target of 30).)
First Posted : August 30, 2012
Results First Posted : October 7, 2019
Last Update Posted : November 5, 2019
- Study Details
- Tabular View
- Study Results
- How to Read a Study Record
|Condition or disease||Intervention/treatment||Phase|
|Traumatic Brain Injury||Drug: Huperzine A Drug: Placebo||Phase 2|
|Study Type :||Interventional (Clinical Trial)|
|Actual Enrollment :||14 participants|
|Intervention Model:||Parallel Assignment|
|Masking:||Double (Participant, Outcomes Assessor)|
|Official Title:||Huperzine A for the Treatment of Cognitive, Mood, and Functional Deficits After Moderate and Severe TBI|
|Actual Study Start Date :||December 2013|
|Actual Primary Completion Date :||August 2018|
|Actual Study Completion Date :||August 2018|
Experimental: Huperzine A
Huperzine A will be administered to patients, titrating dose up from 100mcg/day to 600mcg per day over the course of 20 days - and remaining on the dose of 600mcg/day for the remainder of the drug phase (64 days) - for a total of 12 weeks on Huperzine A.
Drug: Huperzine A
Huperzine A will be administered for 12 weeks as outlined in the Arm Description
Placebo Comparator: Placebo
Placebo will be administered to patients at the same frequency/intervals as the experimental arm (Huperzine-A).
Placebo Arm (blinded randomization) for Huperzine A Intervention
- California Verbal Learning Test- 2nd Edition (CVLT-II): Learning and Memory [ Time Frame: Baseline, 6 weeks, 12 weeks, 24 weeks and at 52 weeks. ]
Measure of learning and memory function. Three indices of the CVLT-II were calculated. The full name, abbreviated name, and the minimum and maximum possible scores of each index are indicated below:
- California Verbal Learning Test- 2nd Edition- Total Learning [CVLT-II-TL] (Minimum score=0; Maximum score= 80)
- California Verbal Learning Test- 2nd Edition- Short delay free recall [CVLT-II-SDFR] (Minimum score=0; Maximum score=16)
- California Verbal Learning Test- 2nd Edition- Long delay free recall [CVLT-II-LDFR] (Minimum score=0; Maximum score=16)
High scores are indicative of greater memory and learning for each index (i.e. better outcome).
- Amplitude of Event Related Potentials (ERPs) P50 and P300 [ Time Frame: Baseline, 12 Weeks ]Event Related Potentials (ERPs): P50 and P300 are neurophysiological measurements that index cortical electrical activity associated with a given stimulus. P50 and P300 were measured using auditory stimuli. P50 represents an index of activity in the cholinergic system and has been used to characterize presynaptic cholinergic deficit. P300 is a measure of general cognitive processing elicited during attention, memory, and executive tasks.
- Latency of Event Related Potentials (ERPs) P50 and P300 [ Time Frame: Baseline, 12 weeks ]Event Related Potentials (ERPs): P50 and P300 are neurophysiological measurements that index cortical electrical activity associated with a given stimulus. P50 and P300 were measured using auditory stimuli. P50 represents an index of activity in the cholinergic system and has been used to characterize presynaptic cholinergic deficit and P300 is a measure of general cognitive processing elicited during attention, memory, and executive tasks.
- Number of Participants Who Experienced Post-traumatic Seizure During 12-week Treatment Window [ Time Frame: Baseline and weekly for 12 weeks. ]To determine whether Huperzine A changes the prevalence of post-traumatic seizure after moderate and severe TBI as compared to placebo at 12 weeks post-enrollment (immediate seizures prevalence).
- Number of Participants With Self-reported Side Effects During 12-week Treatment Window [ Time Frame: Baseline and weekly for 12 weeks. ]To evaluate the safety and tolerability of Huperzine A in this patient population as compared to placebo the frequency of self-reported side effects during the 12-week treatment window were grouped categorically by system (behavioral, cardiac-respiratory, dermatological,gastrointestinal, genitourinary/neurological, hematological, musculoskeletal, neurological).
Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.
|Ages Eligible for Study:||18 Years to 65 Years (Adult, Older Adult)|
|Sexes Eligible for Study:||All|
|Accepts Healthy Volunteers:||No|
- Males and females aged 18 to 65
- Moderate or severe TBI, based on admission Emergency Room GCS 3-12
- All subjects will be greater than 2 weeks, but no more than 1 year, after the qualifying TBI, and will be symptomatic at enrollment (i.e. all subjects will exhibit evidence of ongoing posttraumatic amnesia via the Galveston Orientation Amnesia test (GOAT), or score at least 1.5 SD below the mean for completion time on Part B of the Trail Making Test.
- Agreement to undergo no changes in concomitant medications (including dietary supplements) or therapeutic interventions during the first 12 weeks of the study (that is, the 12 weeks of dosing with study drug), except where medically indicated. Stable concomitant drug regimen (greater than two weeks pre-enrollment without changes)
- Normal swallowing
- English-speaking (since not all of the outcome metrics are normed outside of the English language)
- Patient can be on seizure medication.
- Patients taking acetylcholinesterase inhibitors and other cholinergic and anticholinergic drugs (e.g., tacrine, physostigmine, velnacrine, donepezil, rivastigmine, metrifonate) and CYP1A inducing drugs.
- Evidence of more than 1 seizure in the past 4 weeks prior to enrollment: Patients may not be enrolled if there is evidence of more than one seizure (clinical or electrographic, but not including epileptiform or other irritative discharges) during the 4 weeks prior to enrollment.
- Premorbid history of epilepsy with seizure frequency >1 per month: Patients with a history of idiopathic epilepsy may not be enrolled if their seizure frequency was > 1 per month in the 3 months prior to injury. If pre-injury seizure frequency was < 1 per month but there is documented evidence that post-injury seizure frequency is > 1 per month or there is documented evidence of an increase in the severity or duration of a single seizure relative to the premorbid history, the patient must be excluded.
- Evidence of premorbid major CNS disorder, developmental disorder, psychiatric disorder or substance abuse: Prior to sustaining TBI, patient was diagnosed and/or treated for a major neurologic condition, pervasive developmental disorder (e.g., mental retardation, autism), psychiatric disorder or substance abuse that continued to produce functional disability up to the time of injury.
Individuals with disorders of consciousness, as defined at the time of screening of having vegetative and/or minimally conscious state, will not be enrolled. However, these patients may be followed until they:
- Meet eligibility criteria
- Are more than 12 weeks post injury
- Are discharged
- Pregnancy, as determined by urine hCG testing before randomization
- Breast feeding females
- Significant hematologic, renal or hepatic dysfunction [Hepatic/renal dysfunction is generally identified as lab results > two times the upper limits of normal (ULN), and hematologic dysfunction is determined by clinically significant abnormal lab results], on baseline laboratory examination.
- Slow heart rate (bradycardia) or other heart conditions related to rate
- History of peptic ulcer disease
- History of asthma or emphysema
- History of GI/urinary tract blockages (i.e. ileus, IBS)
- History of glaucoma
To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.
Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT01676311
|United States, Massachusetts|
|Spaulding Rehabilitation Hospital|
|Charlestown, Massachusetts, United States, 02129|
|Principal Investigator:||Ross Zafonte, DO||Spaulding Rehabilitation Hospital|
Documents provided by Ross D. Zafonte, MD, Spaulding Rehabilitation Hospital:
|Responsible Party:||Ross D. Zafonte, MD, Principal Investigator, Spaulding Rehabilitation Hospital|
|Other Study ID Numbers:||
|First Posted:||August 30, 2012 Key Record Dates|
|Results First Posted:||October 7, 2019|
|Last Update Posted:||November 5, 2019|
|Last Verified:||October 2019|
transcranial magnetic stimulation
chinese club moss
Brain Injuries, Traumatic
Central Nervous System Diseases
Nervous System Diseases
Trauma, Nervous System
Wounds and Injuries
Molecular Mechanisms of Pharmacological Action
Physiological Effects of Drugs